| Literature DB >> 33666415 |
Tanja C Knaab1, Jana Held2,3, Bjoern B Burckhardt4, Kelly Rubiano5, John Okombo5, Tomas Yeo5, Sachel Mok5, Anne-Catrin Uhlemann6, Beate Lungerich1, Christoph Fischli7,8, Lais Pessanha de Carvalho2, Benjamin Mordmüller2,3, Sergio Wittlin7,8, David A Fidock5,6, Thomas Kurz1.
Abstract
3-Hydroxypropanamidines are a new promising class of highly active antiplasmodial agents. The most active compound 22 exhibited excellent antiplasmodial in vitro activity with nanomolar inhibition of chloroquine-sensitive and multidrug-resistant parasite strains ofPlasmodium falciparum (with IC50 values of 5 and 12 nM against 3D7 and Dd2 strains, respectively) as well as low cytotoxicity in human cells. In addition, 22 showed strong in vivo activity in thePlasmodium berghei mouse model with a cure rate of 66% at 50 mg/kg and a cure rate of 33% at 30 mg/kg in the Peters test after once daily oral administration for 4 consecutive days. A quick onset of action was indicated by the fast drug absorption shown in mice. The new lead compound was also characterized by a high barrier to resistance and inhibited the heme detoxification machinery in P. falciparum.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33666415 PMCID： PMC8211464 DOI： 10.1021/acs.jmedchem.0c01744
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446